Hypercalcaemia
Summary
Hypercalcaemia is defined as serum calcium greater than 2.6 mmol/L (adjusted for albumin). It is a common metabolic abnormality with potentially life-threatening consequences if severe (greater than 3.5 mmol/L). Primary hyperparathyroidism and malignancy account for over 90% of cases. Symptoms classically remembered as "bones, stones, groans, and moans." Treatment of severe hypercalcaemia is an emergency requiring aggressive IV fluid resuscitation followed by bisphosphonates. [1,2]
Key Facts
- Definition: Adjusted calcium greater than 2.6 mmol/L (check albumin correction).
- Severe: Greater than 3.5 mmol/L (medical emergency).
- Two Main Causes: Primary hyperparathyroidism (90% outpatient), Malignancy (70% inpatient). [3]
- Key Discriminator: PTH level - elevated or inappropriately normal in hyperparathyroidism; suppressed in malignancy.
- Classic Symptoms: "Bones, stones, groans, and moans" + polyuria.
- Acute Treatment: IV saline rehydration → bisphosphonates.
Clinical Pearls
The 90-90 Rule: Primary hyperparathyroidism (PHPT) + malignancy cause 90% of hypercalcaemia. In the community, 90% is PHPT. In hospital, malignancy predominates.
Check the PTH First: PTH is the key discriminating test. High/inappropriate normal = PTH-mediated (PHPT, FHH, lithium). Suppressed = non-PTH mediated (malignancy, granulomatous disease, vitamin D toxicity).
Malignancy-Related Hypercalcaemia is a Poor Prognostic Sign: Median survival is 30 days after diagnosis of hypercalcaemia of malignancy. Consider goals of care discussion.
Short QT on ECG: Hypercalcaemia shortens the QT interval (opposite of hypocalcaemia). May cause arrhythmias.
Incidence and Demographics
- Overall Prevalence: 1-2% of general population.
- Primary Hyperparathyroidism: 1-3 per 1,000; increases with age.
- Malignancy-Associated: 10-30% of cancer patients at some point.
- Sex: PHPT more common in women (3:1); HHM more equal.
- Age: PHPT peaks post-menopause; malignancy varies by cancer type.
Causes of Hypercalcaemia
PTH-Mediated (PTH Elevated or Inappropriately Normal)
| Cause | Notes |
|---|---|
| Primary Hyperparathyroidism | Single adenoma (85%), Hyperplasia (15%), Carcinoma (less than 1%) |
| Tertiary Hyperparathyroidism | After prolonged secondary (CKD); autonomous PTH secretion |
| Familial Hypocalciuric Hypercalcaemia (FHH) | CaSR mutation; benign; low urinary calcium excretion |
| Lithium Therapy | Shifts PTH set-point; reversible |
| MEN Syndromes | MEN1, MEN2A include hyperparathyroidism |
Non-PTH Mediated (PTH Suppressed)
| Cause | Mechanism |
|---|---|
| Malignancy | Bone metastases (breast, lung, prostate, myeloma); PTHrP secretion (squamous cancers); 1,25-Vit D production (lymphoma) |
| Granulomatous Disease | Sarcoidosis, TB → macrophage 1-alpha hydroxylase → ↑1,25(OH)2D |
| Vitamin D Intoxication | Excess supplementation or dermal production |
| Milk-Alkali Syndrome | Excessive calcium carbonate + alkali intake |
| Thyrotoxicosis | Increased bone turnover |
| Immobilisation | Particularly in Paget's, young patients |
| Drugs | Thiazides, Vitamin A toxicity |
Step 1: Normal Calcium Homeostasis
- Normal Range: 2.2-2.6 mmol/L (adjusted).
- Key Regulators: PTH, Vitamin D, Calcitonin (minor role).
- PTH: ↑Bone resorption, ↑Renal calcium reabsorption, ↑1,25-Vit D synthesis.
- Vitamin D: ↑Intestinal calcium absorption, ↑Bone resorption.
Step 2: Mechanisms of Hypercalcaemia
Primary Hyperparathyroidism
- Autonomous PTH secretion (adenoma usually).
- Loss of normal feedback inhibition.
- Increased bone resorption + renal calcium reabsorption + 1,25-Vit D.
Hypercalcaemia of Malignancy Three main mechanisms:
- Humoral Hypercalcaemia (HHM): Tumour secretes PTHrP → mimics PTH actions. Common in squamous cell carcinomas.
- Osteolytic Metastases: Direct bone destruction by tumour → calcium release. Common in breast, lung, prostate, myeloma.
- Calcitriol Production: Lymphomas produce 1,25(OH)2D → ↑intestinal calcium absorption.
Granulomatous Disease
- Activated macrophages express 1-alpha hydroxylase.
- Unregulated conversion of 25-OH-D to 1,25(OH)2D.
- Increased intestinal calcium absorption.
Step 3: Systemic Effects
HYPERCALCAEMIA
↓
┌────────────┼────────────┐
↓ ↓ ↓
NEUROLOGICAL RENAL CARDIOVASCULAR
↓ ↓ ↓
Confusion Polyuria Short QT
Lethargy Nephrogenic Bradycardia
Coma DI Arrhythmias
Stones HTN
AKI
Step 4: Organ-Specific Effects
| System | Mechanism | Clinical Effect |
|---|---|---|
| Renal | ADH resistance (nephrogenic DI) | Polyuria, polydipsia, dehydration |
| Nervous | Neuronal membrane stabilisation | Confusion, lethargy, coma |
| Cardiac | Calcium influx effects | Short QT, bradycardia, arrhythmias |
| GI | Smooth muscle dysfunction | Constipation, nausea, anorexia, pancreatitis |
| Skeletal | Bone resorption | Osteoporosis, fractures (PHPT) |
Classic Mnemonic: "Bones, Stones, Groans, and Moans"
Additional Features
Symptoms by Severity
| Severity | Calcium Level | Symptoms |
|---|---|---|
| Mild | 2.6-3.0 mmol/L | Often asymptomatic or vague fatigue |
| Moderate | 3.0-3.5 mmol/L | Polyuria, constipation, nausea, mild confusion |
| Severe | Greater than 3.5 mmol/L | Severe confusion, cardiac arrhythmias, coma, can be fatal |
Red Flags - "The Don't Miss" Signs
- Calcium greater than 3.5 mmol/L → Emergency; aggressive treatment.
- Altered consciousness → May indicate severe hypercalcaemia or CNS metastases.
- Cardiac symptoms/ECG changes → Short QT, arrhythmias.
- Suspected malignancy → Weight loss, new mass, bone pain.
- Hypercalcaemic crisis → AKI, dehydration, cardiac arrhythmias.
General Assessment
- Hydration status (dry mucous membranes, reduced skin turgor).
- Conscious level (confusion, drowsiness).
- Vital signs (BP, pulse - bradycardia).
Focused Examination
Head and Neck
- Goitre or thyroid nodule (thyrotoxicosis, parathyroid pathology).
- Cervical lymphadenopathy (malignancy, sarcoidosis).
- Band keratopathy (chronic hypercalcaemia - rare).
Chest
- Lung examination (consolidation, effusion - malignancy).
- Breast examination if appropriate.
Abdomen
- Abdominal masses (renal, hepatic).
- Renal angle tenderness (stones).
Skeletal
- Bone tenderness (metastases, myeloma).
- Kyphosis, height loss (osteoporosis).
Neurological
- Muscle weakness (proximal myopathy).
- Hypo/hyperreflexia (variable).
- Mental state assessment.
Clues to Underlying Cause
| Finding | Suggests |
|---|---|
| Enlarged parathyroids (rarely palpable) | PHPT |
| Lymphadenopathy, organomegaly | Sarcoidosis, lymphoma |
| Bony tenderness, fractures | Myeloma, metastases |
| Cachexia | Malignancy |
| Skin lesions | Sarcoidosis (lupus pernio) |
First-Line Investigations
Biochemistry
| Test | Purpose | Interpretation |
|---|---|---|
| Serum Calcium (adjusted) | Confirm hypercalcaemia | Adjust for albumin |
| Albumin | Calcium correction | Adjusted Ca = measured Ca + 0.02 × (40 - albumin) |
| PTH (Parathyroid Hormone) | KEY discriminating test | High/normal = PHPT; Low/suppressed = malignancy |
| Phosphate | Typically low in PHPT | Low in PHPT; may be high in granulomatous |
| ALP | Bone turnover | Elevated in bone mets, Paget's |
| U&E/Creatinine | Renal function | AKI from dehydration |
| Magnesium | Co-existing abnormality | May be low |
Calcium Correction Formula Adjusted Calcium = Measured Calcium + 0.02 × (40 - Albumin)
Second-Line (Based on PTH Result)
If PTH Elevated or Inappropriately Normal:
| Test | Purpose |
|---|---|
| 24-hour urine calcium/creatinine | Differentiates PHPT from FHH (FHH has low urinary calcium clearance ratio less than 0.01) |
| PTH again | Confirm if borderline |
| Parathyroid Imaging | Sestamibi scan, neck USS, 4D-CT (if surgery planned) |
| DEXA scan | Assess bone density |
| Genetic testing | If FHH suspected or MEN |
If PTH Suppressed:
| Test | Purpose |
|---|---|
| PTHrP | Humoral hypercalcaemia of malignancy |
| Vitamin D metabolites | 25-OH-D (intoxication), 1,25(OH)2D (granulomatous, lymphoma) |
| Serum/Urine protein electrophoresis | Myeloma screen |
| Chest X-ray | Malignancy, sarcoidosis |
| CT TAP | Staging if malignancy suspected |
| ACE level | Sarcoidosis |
ECG
- Short QT interval: Characteristic finding.
- Bradycardia, AV block (severe).
- Arrhythmias.
Management Algorithm
CONFIRMED HYPERCALCAEMIA
(Adjusted calcium greater than 2.6 mmol/L)
↓
┌─────────────────────────────────────────────┐
│ ASSESS SEVERITY │
│ Mild: 2.6-3.0 Moderate: 3.0-3.5 │
│ Severe: greater than 3.5 mmol/L │
└─────────────────────────────────────────────┘
↓
┌───────────┴───────────┐
↓ ↓
MILD/MODERATE SEVERE
(Asymptomatic) (or Symptomatic)
↓ ↓
Investigate cause EMERGENCY
Outpatient if stable TREATMENT
↓
┌─────────────────────────────────────────────┐
│ 1. IV SALINE (aggressive rehydration) │
│ 3-6L in first 24 hours │
│ 2. IV BISPHOSPHONATE │
│ Zoledronate 4mg OR Pamidronate 60-90mg │
│ 3. Treat underlying cause │
│ 4. Consider: Steroids, Calcitonin, │
│ Denosumab, Dialysis │
└─────────────────────────────────────────────┘
Acute Treatment of Severe Hypercalcaemia
Step 1: IV Fluid Resuscitation
- 0.9% Normal Saline: 3-6 litres in first 24 hours.
- Mechanism: Expands volume; increases renal calcium excretion.
- Monitor: Fluid balance, urine output (target greater than 200mL/hr).
- Caution: Cardiac failure risk in elderly.
Step 2: IV Bisphosphonate
- Zoledronate 4mg IV (preferred) or Pamidronate 60-90mg IV.
- Mechanism: Inhibits osteoclast-mediated bone resorption.
- Onset: 2-4 days for effect.
- Precaution: Avoid if eGFR less than 30 (renal injury risk).
Step 3: Additional Therapies (If Needed)
| Therapy | Indication | Mechanism |
|---|---|---|
| Calcitonin (SC/IM) | Bridge while awaiting bisphosphonate | Rapid but transient effect (tachyphylaxis after 48h) |
| Corticosteroids | Sarcoidosis, lymphoma, myeloma, Vit D toxicity | Reduces 1,25-Vit D production |
| Denosumab | Refractory or bisphosphonate contraindicated | RANKL inhibitor; potent |
| Dialysis | Renal failure, refractory hypercalcaemia | Removes calcium directly |
Specific Treatments by Cause
Primary Hyperparathyroidism
- Mild asymptomatic: Monitor or surgery if meeting criteria.
- Symptomatic/severe: Surgery (parathyroidectomy) is curative.
- Cinacalcet: Calcimimetic for those unsuitable for surgery.
Malignancy
- Treat underlying cancer.
- Bisphosphonates/denosumab for ongoing management.
- Palliative care discussion if prognosis poor.
Granulomatous Disease
- Corticosteroids (effective).
- Avoid sun exposure, vitamin D supplements.
Vitamin D Toxicity
- Stop vitamin D supplements.
- Steroids if needed.
- Hydration.
What NOT to Do
- Avoid thiazide diuretics: Increase calcium reabsorption.
- DO NOT use loop diuretics routinely: Only if fluid overload.
- Do not delay investigation: PTH is key.
Acute Complications
| Complication | Features | Management |
|---|---|---|
| Hypercalcaemic crisis | Severe dehydration, AKI, coma | Aggressive IV fluids, ICU |
| Cardiac arrhythmias | Short QT, bradycardia, arrest | Cardiac monitoring, treat calcium |
| Acute kidney injury | Vasoconstriction, dehydration | IV fluids; avoid nephrotoxins |
| Pancreatitis | Abdominal pain, raised amylase | Supportive care |
Chronic Complications
| Complication | Cause |
|---|---|
| Nephrolithiasis | Hypercalciuria → calcium stones |
| Nephrocalcinosis | Calcium deposition in renal parenchyma |
| Chronic kidney disease | Chronic nephrocalcinosis |
| Osteoporosis | Increased bone resorption (PHPT) |
| Peptic ulcer disease | Increased gastrin secretion |
Complications of Treatment
| Treatment | Complication |
|---|---|
| Bisphosphonates | Osteonecrosis of jaw (rare), renal injury, hypocalcaemia |
| Denosumab | Hypocalcaemia, osteonecrosis of jaw |
| Surgery | Hypocalcaemia (hungry bone syndrome), recurrent laryngeal nerve injury |
Prognosis by Cause
| Cause | Prognosis |
|---|---|
| Primary Hyperparathyroidism | Excellent with surgery; cure rate greater than 95% |
| Hypercalcaemia of Malignancy | Poor; median survival 30 days; reflects advanced disease |
| Granulomatous Disease | Good with treatment |
| Vitamin D Toxicity | Excellent if identified and stopped |
Hypercalcaemia of Malignancy
- Indicates advanced or disseminated disease.
- Median survival approximately 30 days from diagnosis.
- Important to discuss prognosis and goals of care.
Monitoring
- Recheck calcium within 24-48 hours of treatment.
- Long-term monitoring for PHPT if conservative management.
- Follow-up for underlying malignancy.
Key Guidelines
| Guideline | Organisation | Key Recommendations |
|---|---|---|
| Society for Endocrinology Emergency Guidance | UK | IV saline + bisphosphonates for severe |
| Fourth International Workshop on PHPT | International | Surgical criteria for asymptomatic PHPT |
| ASCO Guidelines | USA | Management of hypercalcaemia of malignancy |
Landmark Studies
1. Bilezikian et al. PHPT Guidelines (2014) [5]
- Question: When to operate on asymptomatic PHPT?
- Criteria: Calcium greater than 0.25 mmol/L above normal; age less than 50; T-score less than -2.5; eGFR less than 60; nephrolithiasis.
- Impact: Standardised surgical indications.
- PMID: 25078146.
2. Major et al. Zoledronate vs Pamidronate (2001) [6]
- Question: Zoledronate vs pamidronate for hypercalcaemia of malignancy?
- N: 287 patients.
- Result: Zoledronate superior response rate and duration.
- Impact: Zoledronate became preferred bisphosphonate.
- PMID: 11304472.
3. Hu et al. Denosumab (2014)
- Question: Denosumab for bisphosphonate-refractory hypercalcaemia?
- Result: Effective in reducing calcium in refractory cases.
- Impact: Alternative for bisphosphonate failure.
- PMID: 24446653.
What is Hypercalcaemia?
Hypercalcaemia means there is too much calcium in your blood. Calcium is important for bones, nerves, and muscles, but too much can cause problems.
What Causes It?
The two most common causes are:
- Overactive parathyroid glands (small glands in the neck that control calcium).
- Cancer – some cancers can raise calcium levels.
Other causes include excessive vitamin D, certain medications, and some inflammatory conditions.
What Are the Symptoms?
Mild hypercalcaemia may have no symptoms. Higher levels can cause:
- Tiredness and weakness.
- Excessive thirst and urinating a lot.
- Nausea, loss of appetite, constipation.
- Confusion or difficulty thinking clearly.
- Bone pain.
- Kidney stones.
Doctors remember these as: "Bones, stones, groans, and moans."
How is it Diagnosed?
- Blood tests to check calcium levels and parathyroid hormone (PTH).
- Sometimes further tests including scans if a cause like cancer is suspected.
How is it Treated?
- Fluids: Through a drip (IV) to flush out excess calcium.
- Medications: Bisphosphonates (e.g., zoledronate) to reduce calcium.
- Treating the cause: Surgery for parathyroid adenoma; cancer treatment if that's the cause.
When to Seek Help
- Severe confusion or drowsiness.
- Persistent vomiting or not able to drink.
- Palpitations or chest discomfort.
- Severe bone pain.
What is the Outlook?
- If caused by overactive parathyroid glands, surgery is usually very successful.
- If caused by cancer, treatment focuses on controlling calcium levels and managing the underlying disease.
Primary Sources
- Ahmad S, et al. Hypercalcaemia: an evidence-based approach to clinical cases. Clin Med (Lond). 2016;16:277-281. PMID: 27251920.
- Minisola S, et al. The diagnosis and management of hypercalcaemia. BMJ. 2015;350:h2723. PMID: 26037642.
- Stewart AF. Hypercalcemia associated with cancer. N Engl J Med. 2005;352:373-379. PMID: 15673803.
- Society for Endocrinology. Acute hypercalcaemia emergency guidance. https://www.endocrinology.org/clinical-practice/clinical-guidance/. Accessed 2025.
- Bilezikian JP, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab. 2014;99:3561-3569. PMID: 25078146.
- Major P, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy. J Clin Oncol. 2001;19:558-567. PMID: 11208851.
Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists.